Chenhui Deng

535 total citations
31 papers, 253 citations indexed

About

Chenhui Deng is a scholar working on Surgery, Artificial Intelligence and Pharmacology. According to data from OpenAlex, Chenhui Deng has authored 31 papers receiving a total of 253 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Surgery, 4 papers in Artificial Intelligence and 4 papers in Pharmacology. Recurrent topics in Chenhui Deng's work include Inflammatory Bowel Disease (4 papers), Systemic Lupus Erythematosus Research (3 papers) and Biosimilars and Bioanalytical Methods (3 papers). Chenhui Deng is often cited by papers focused on Inflammatory Bowel Disease (4 papers), Systemic Lupus Erythematosus Research (3 papers) and Biosimilars and Bioanalytical Methods (3 papers). Chenhui Deng collaborates with scholars based in China, United States and Sweden. Chenhui Deng's co-authors include Zhiru Zhang, Tianyan Zhou, Debjit Pal, Zhijing Li, Ecenur Ustun, Rujia Xie, Hanqing Li, Wei Lu, Mingjie Liu and David Z. Pan and has published in prestigious journals such as Blood, Gastroenterology and Optics Express.

In The Last Decade

Chenhui Deng

28 papers receiving 249 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Chenhui Deng China 10 62 49 31 30 29 31 253
Jiyong Wu China 9 10 0.2× 8 0.2× 9 0.3× 22 0.7× 89 3.1× 30 591
Andrew Wilson United States 9 26 0.4× 159 3.2× 19 0.6× 27 0.9× 18 0.6× 44 346
Simon Lam United Kingdom 13 7 0.1× 16 0.3× 9 0.3× 65 2.2× 214 7.4× 34 521
Yunlu Liu China 8 22 0.4× 4 0.1× 28 0.9× 18 0.6× 156 5.4× 23 335
Zhiyong Xu China 9 9 0.1× 25 0.5× 3 0.1× 29 1.0× 21 0.7× 29 306
Dong Wook Kim South Korea 9 8 0.1× 3 0.1× 30 1.0× 22 0.7× 28 1.0× 40 278
Dongxu Li China 11 24 0.4× 20 0.4× 3 0.1× 51 1.7× 224 7.7× 26 387
John Costello United States 10 36 0.6× 27 0.6× 3 0.1× 127 4.2× 238 8.2× 21 394
Adam Davies United Kingdom 9 72 1.2× 2 0.0× 15 0.5× 5 0.2× 110 3.8× 15 307
Tester F. Ashavaid India 12 10 0.2× 17 0.5× 24 0.8× 122 4.2× 35 335

Countries citing papers authored by Chenhui Deng

Since Specialization
Citations

This map shows the geographic impact of Chenhui Deng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chenhui Deng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chenhui Deng more than expected).

Fields of papers citing papers by Chenhui Deng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chenhui Deng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chenhui Deng. The network helps show where Chenhui Deng may publish in the future.

Co-authorship network of co-authors of Chenhui Deng

This figure shows the co-authorship network connecting the top 25 collaborators of Chenhui Deng. A scholar is included among the top collaborators of Chenhui Deng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chenhui Deng. Chenhui Deng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kong, Lingtao, Yifang Zhou, Chenhui Deng, et al.. (2025). Neurobiological subtypes of adolescent depression: a multimodal integration of morphometric similarity network and spatial transcriptomics. Molecular Psychiatry. 30(11). 5448–5462. 2 indexed citations
2.
Lou, Yan‐Ru, Yongping Xu, Yifeng Xiong, Chenhui Deng, & Qinghua Wang. (2025). Population Pharmacokinetics of Efsubaglutide Alfa in Healthy Subjects and Subjects with Type 2 Diabetes. Clinical Pharmacokinetics. 64(4). 533–552. 5 indexed citations
5.
Luo, Ping, Guoping Yang, Shaihong Zhu, et al.. (2022). Population pharmacokinetics of omeprazole in obese and normal-weight adults. Expert Review of Clinical Pharmacology. 15(4). 461–471. 4 indexed citations
6.
Yang, Xinyu, et al.. (2022). Directional solidification, nanoindentation and thermionic properties of LaB6(100)-ZrB2 eutectic composite. Journal of the European Ceramic Society. 42(6). 2726–2734. 6 indexed citations
7.
Pal, Debjit, et al.. (2021). GLAIVE: Graph Learning Assisted Instruction Vulnerability Estimation. 82–87. 3 indexed citations
9.
Xie, Rujia, Chenhui Deng, Qiang Wang, et al.. (2019). Population pharmacokinetics of tofacitinib in patients with psoriatic arthritis. International Journal of Clinical Pharmacology and Therapeutics. 57(9). 464–473. 18 indexed citations
10.
Deng, Chenhui, et al.. (2018). Channel likelihood correction for photon-counting array receivers in the presence of dead time and jitters. Optics Express. 26(3). 2848–2848. 4 indexed citations
11.
Mukherjee, Arnab, Geert D’Haens, William J. Sandborn, et al.. (2017). Pharmacokinetics and Exposure-Response of Tofacitinib in a Phase 3 Maintenance Study in Ulcerative Colitis Patients. Gastroenterology. 152(5). S595–S596. 2 indexed citations
12.
Deng, Chenhui, Elodie L. Plan, & Mats O. Karlsson. (2016). Approaches for modeling within subject variability in pharmacometric count data analysis: dynamic inter-occasion variability and stochastic differential equations. Journal of Pharmacokinetics and Pharmacodynamics. 43(3). 305–314. 10 indexed citations
13.
Mukherjee, Arnab, Chenhui Deng, Rujia Xie, et al.. (2016). Mo1780 Tofacitinib Pharmacokinetics and Durability of Drug Exposure in Moderate to Severe Crohn's Disease Patients in Phase 2 Induction and Maintenance Studies. Gastroenterology. 150(4). S774–S774. 1 indexed citations
14.
Shang, Dewei, Kehua Wu, Anning Li, et al.. (2016). Population pharmacokinetic-pharmacodynamic (PopPK/PD) modeling of risperidone and its active metabolite in Chinese schizophrenia patients. International Journal of Clinical Pharmacology and Therapeutics. 54(5). 378–389. 3 indexed citations
16.
Wu, Qiong, Mengyao Li, Hanqing Li, et al.. (2013). Pharmacokinetic-pharmacodynamic modeling of the anticancer effect of erlotinib in a human non-small cell lung cancer xenograft mouse model. Acta Pharmacologica Sinica. 34(11). 1427–1436. 15 indexed citations
17.
Deng, Chenhui, et al.. (2013). Initial dosage regimens of vancomycin for Chinese adult patients based on population pharmacokinetic analysis. International Journal of Clinical Pharmacology and Therapeutics. 51(5). 407–415. 21 indexed citations
18.
Wang, Xipei, Dewei Shang, Jakob Ribbing, et al.. (2012). Placebo effect model in asthma clinical studies: longitudinal meta-analysis of forced expiratory volume in 1 second. European Journal of Clinical Pharmacology. 68(8). 1157–1166. 14 indexed citations
19.
Li, Liang, Zaiquan Li, Chenhui Deng, et al.. (2012). A mechanism-based pharmacokinetic/pharmacodynamic model for CYP3A1/2 induction by dexamethasone in rats. Acta Pharmacologica Sinica. 33(1). 127–136. 26 indexed citations
20.
Wu, Kehua, Tao Guo, Chenhui Deng, et al.. (2012). Population pharmacokinetics of modafinil acid and estimation of the metabolic conversion of modafinil into modafinil acid in 5 major ethnic groups of China. Acta Pharmacologica Sinica. 33(11). 1401–1408. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026